Premium
Immunosuppressive therapy in childhood‐onset arrhythmogenic inflammatory cardiomyopathy
Author(s) -
Peretto Giovanni,
Barzaghi Federica,
Cicalese Maria Pia,
Di Resta Chiara,
Slavich Massimo,
Benedetti Sara,
Giangiobbe Sara,
Rizzo Stefania,
Palmisano Anna,
Esposito Antonio,
De Cobelli Francesco,
Gulletta Simone,
Basso Cristina,
Casari Giorgio,
Aiuti Alessandro,
Della Bella Paolo,
Sala Simone
Publication year - 2021
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1111/pace.14153
Subject(s) - medicine , cardiomyopathy , myocarditis , refractory (planetary science) , cardiology , troponin , anakinra , intensive care medicine , heart failure , disease , physics , astrobiology , myocardial infarction
We present, to our knowledge, the first case of immunosuppressive therapy (IST) application in a 12‐year‐old child with arrhythmogenic inflammatory cardiomyopathy resulting from the overlap between autoimmune myocarditis and primary arrhythmogenic cardiomyopathy. Indication to off‐lable IST was compelling, because of recurrent drug‐refractory ventricular arrhythmias (VAs). We show that IST was feasible, safe, and effective on multiple clinical endpoints, including symptoms, VA recurrences, and T‐troponin release. Remarkably, all diagnostic and therapeutic strategies were worked out by a dedicated multidisciplinary team, including specialized pediatric immunologists.